GlobeNewswire·Aug 6, 2026, 4:06 PM ET

iRhythm to Acquire VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm Holdings announced a definitive agreement to acquire VitalConnect for approximately $287.5 million to expand its ambulatory cardiac monitoring portfolio.
The transaction consideration consists of roughly $237.5 million in cash funded from iRhythm's existing balance sheet & approximately $50 million in iRhythm common stock.
iRhythm will provide VitalConnect with interim working capital financing up to a maximum of $30 million to fund operations prior to closing.
Upon closing, the combination adds mobile cardiac telemetry (MCT) & continuous multi-vitals monitoring capabilities to iRhythm's existing Zio platform.
VitalConnect's FDA-cleared platform supports up to 11 physiological parameters & offers flexible service models including up to 30-day patient monitoring.
The deal is expected to enhance iRhythm's revenue growth rate beginning in 2027 while maintaining a 15% adjusted EBITDA margin target for that year.
iRhythm's commercial scale & health system relationships are anticipated to accelerate VitalConnect's growth & expand customer access across hospital & remote care settings.
The transaction is expected to close by the end of 2026, subject to regulatory & customary closing conditions.
iRhythm management will discuss the transaction & second quarter 2026 financial results on a conference call on August 6, 2026, at 1:30 p.m. Pacific time.